S2 S. Salloway research in this area is required to provide appropriate evidence of therapeutic benefit, these early results provide signals supporting the potential efficacy of donepezil in MCI.
At the other end of the spectrum, our efforts must focus on alleviating the symptoms and improving the quality of life of those patients affected by severe dementia. Professor Bengt Winblad presented new data from a randomized, controlled trial in which donepezil was found to have significant benefit over placebo in improving cognition and the ability to perform activities relating to daily life in patients with severe AD. These data suggest that donepezil may be effective not only in mild to moderate dementia, but also in more severe stages of AD.
These presentations all highlighted the vital role played by cholinesterase inhibitors in the comprehensive treatment strategies used in AD. New and emerging data suggest that these agents are effective across the entire spectrum of the disease and not solely in the mild to moderate stages for which they are currently licensed. Furthermore, ongoing studies of AD pathology have led to an increased awareness that cholinesterase inhibitors may have effects beyond enhanced cholinergic transmission. Our aim must now be to slow progression of AD, prolong the time spent in the milder stages of cognitive impairment and protect the autonomy of affected patients. Cholinesterase inhibitor therapy is clearly central to achieving these goals. 
